Agenus Inc
AGEN.O- Latest Trade
- trading lower2.55USD
- -0.08
- 3.04%
- As of Jan 31 2023. Values delayed up to 15 minutes
- Day Range
- 2.55 - 2.68
- 52-Week Range
- 1.25 - 3.37
- Previous Close
- 2.63
- Open
- 2.60
- Volume
- 3,451,569.00
- 3 Month Average Trading Volume
- 90.97
- Shares Out (Mil)
- 294.95
- Market Cap
- 744.72
- Forward P/E
- -3.41
- Dividend Yield
- 0.00
Key Statistics
1.6 mean rating - 5 analysts
- P/E Excl. Extra Items (TTM)
- 0.00
- Price To Sales (TTM)
- 8.28
- Price To Book (Quarterly)
- 0.00
- Price To Cash Flow (Per Share TTM)
- 0.00
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -82.84
- Return On Equity (TTM)
- -51.73
2021 (millions USD)
About Agenus Inc (AGEN.O)
Company Information
Agenus Inc. is a clinical-stage immuno-oncology (I-O) company. It has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, vaccines and adjuvants. Its antibody candidates are Balstilimab (an anti-PD-1 antibody) and Zalifrelimab (an anti-CTLA-4 antibody), which is in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Its clinical-stage asset portfolio also includes Botensilimab (AGEN1181), AGEN2373, AGEN1423, AGEN1777, MK-4830, INCAGN2390, INCAGN2385 and AGENT 797. It is developing personalized vaccines, namely Prophage and AutoSynVax, and off-the-shelf vaccines PhosphoSynVax, which contains heat shock proteins to deliver neoantigens to the right immune cells to activate an anti-cancer immune response.
Address
3 Forbes RdLEXINGTON, MA
02421-7305
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Garo H. Armen
- Chairman of the Board, Chief Executive Officer, Co-Founder
- Christine M. Klaskin
- Vice President - Finance
- Patricia Carlos
- Chief Regulatory, Quality, and Safety Officer
- Steven O'Day
- Chief Medical Officer
- Timothy R. Wright
- Lead Independent Director
- Brian J. Corvese
- Independent Director
- Susan B. Hirsch
- Independent Director
- Allison M. Jeynes-Ellis
- Independent Director
- Ulf Wiinberg
- Independent Director
Latest News
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
Future | Last | % Change |
---|---|---|
Gold | 1,922.30 | 0.03% |
Copper | 781.95 | 0.17% |
Brent Crude Oil | 84.90 | -- |
CBOT Soybeans | 1,530.25 | 0.33% |
Stocks
Index | Last | % Change |
---|---|---|
S&P 500 | 4,017.77 | 1.30% |
Euro STOXX 50 | 4,158.63 | 0.46% |
FTSE 100 | 7,784.87 | 0.25% |
Nikkei 225 | 27,442.36 | 0.03% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes